FDA PreCheck Pilot Program to Build Manufacturing Readiness

The U.S. Food and Drug Administration (FDA) PreCheck Pilot Program signals a new approach to pharmaceutical manufacturing oversight.

Rather than engaging with manufacturers only as products approach approval or facilities prepare for inspection, the programme encourages earlier collaboration to strengthen manufacturing readiness, quality systems, and operational maturity.

Image

What Is the FDA PreCheck Pilot Program?

The FDA PreCheck Pilot Program is a voluntary initiative that enables selected pharmaceutical manufacturers to engage with U.S. Food and Drug Administration (FDA) experts during facility development and manufacturing preparation.

Launched as part of the FDA's wider efforts to support domestic U.S. drug manufacturing, the pilot reflects the recognised fact that resilient pharmaceutical supply chains begin long before commercial production.

As advanced manufacturing technologies, biologics, and personalised medicines continue to reshape the industry, regulators are placing greater emphasis on helping manufacturers build robust production capabilities from the outset.

Unlike a pre-approval inspection, the programme is not designed to assess regulatory compliance before a product reaches the market.

Instead, the FDA Precheck Pilot Program provides an opportunity for manufacturers to discuss facility design, manufacturing processes, quality systems, digital technologies, and operational readiness while production capabilities are still being established.

Rather than identifying issues after manufacturing systems have been implemented, the FDA is exploring whether earlier regulatory engagement can help manufacturers address potential challenges before they affect commercial production or inspection outcomes.

In many respects, the Precheck programme extends the principles of Quality-by-Design beyond product development and into pharmaceutical manufacturing itself, encouraging quality, consistency, and operational excellence from the earliest stages of facility planning.

View interview How Should Pharma Companies Audit AI Vendors?

How Should Pharma Companies Audit AI Vendors?

“This is one of the riskiest industries there is because you're dealing with human lives, you're dealing with experimental protocols, and you're dealing with regulatory bodies where you might not get another shot at that clinical trial."

Image

Why Is the FDA Changing Its Manufacturing Approach with Its Precheck Pilot Program?

The FDA has consistently emphasised the importance of strengthening U.S. domestic drug manufacturing while supporting the adoption of advanced pharmaceutical manufacturing technologies.

Recent medicine shortages, supply chain disruption, and increasing reliance on overseas manufacturing have highlighted the need for more resilient production capacity within the United States.

At the same time, modern medicines, particularly biologics and advanced therapies, require increasingly sophisticated manufacturing environments supported by digital systems, automation, and robust quality management.

The FDA PreCheck Pilot Program reflects this changing pharma landscape.

Rather than viewing manufacturing solely as the final stage of product development, the agency is encouraging manufacturers to integrate quality, operational readiness, and regulatory thinking much earlier in the process.

For industry, this represents a shift from reactive inspection preparation towards proactive manufacturing readiness, where quality systems and operational capability are developed alongside the medicine itself.

Seven FDA PreCheck Pilot Participants 

The FDA has selected seven organisations to participate in the inaugural PreCheck Pilot Program, representing a diverse cross-section of modern pharmaceutical manufacturing.

The seven PreCheck pilot participants include innovator pharmaceutical companies, biologics manufacturers, and contract development and manufacturing organisations (CDMOs).

The participants reflecting the broad range of manufacturing models that support today's pharmaceutical industry.

Participants include Eli Lilly, FUJIFILM Diosynth Biotechnologies, Genentech, Amgen, Regeneron, National Resilience, and Thermo Fisher Scientific.

The selection is significant because it extends beyond traditional pharmaceutical production.

Several participants are recognised for their investments in biologics, advanced manufacturing technologies, and large-scale contract manufacturing, areas that are becoming increasingly important as therapies grow more complex.

Rather than focusing on one manufacturing model, the pilot enables the FDA to evaluate how earlier regulatory engagement performs across diverse medicinal production environments.

The insights gained from the FDA PreCheck pilot help shape future approaches to manufacturing readiness, operational excellence, and regulatory collaboration across the wider pharmaceutical industry.

Why the U.S. Is Moving Pharma Manufacturing Regulatory Oversight Upstream 

The FDA PreCheck Pilot Program reflects a broader shift in how pharmaceutical manufacturing is viewed.

Historically, manufacturing readiness was often considered a milestone reached towards the end of product development. Today, it is increasingly recognised as a strategic capability that can influence launch timelines, product quality, and long-term supply resilience.

This is particularly true for biologics and advanced therapies. Manufacturing monoclonal antibodies, cell therapies, gene therapies, and other complex biological products requires highly specialised facilities, sophisticated process controls, and mature quality management systems.

Delays in facility readiness or process validation can have significant commercial consequences, even when clinical development remains on schedule.

Earlier regulatory engagement offers manufacturers an opportunity to identify operational risks before they become compliance issues.

Regulatory engagement supports stronger collaboration between Technical Operations, Quality, Manufacturing, and Chemistry, Manufacturing, and Controls (CMC) teams, creating a more integrated approach to commercial readiness.

As pharmaceutical production becomes increasingly digital, incorporating automation, continuous manufacturing, advanced analytics, and AI-enabled monitoring, manufacturing excellence is becoming a key differentiator rather than simply a regulatory requirement.

Image

What Does the FDA PreCheck Pilot Program Mean for the Future of U.S. Pharm Manufacturing?

The FDA has been clear that the PreCheck Pilot Program is not intended to replace existing inspections or alter regulatory standards.

Instead, the programme represents a more proactive approach to supporting manufacturers as facilities and production systems become increasingly complex.

Earlier collaboration with regulators has the potential to improve manufacturing readiness, strengthen quality systems, reduce avoidable delays, and support more resilient domestic production.

While the long-term outcomes of this programme remain to be evaluated, it signals a growing recognition that manufacturing strategy should be developed alongside product strategy, not after it.

As investment in U.S. domestic manufacturing, advanced production technologies, and biologics continues to grow, initiatives such as PreCheck may become an increasingly important component of modern pharmaceutical Technical Operations.

At Pharmatica, we examine the regulatory developments, manufacturing innovations, and operational strategies shaping the future of pharmaceutical production. Our independent analysis helps Technical Operations leaders understand how quality, technology, and regulatory science are transforming medicine manufacturing.

Pharmatica: Insight. Connection. Impact.